Sangamo Therapeutics, Inc
- Close
- Oct 23, 2026 · +0.00%
- Market cap
- $49.71M
- 414.29M shares
- Filings
- 1,019
Q1 2026−31.6% FY25 yoy
Q1 2026N/M FY25 yoy
Q1 2026N/M FY25 yoy
Q1 2026derivedN/M FY25 yoy
Q1 2026N/M FY25 yoy
Q1 2026−50.0% FY25 yoy
- $49.71M
- —
- 1.4×
- —
- -181.95%
- —
Twelve months to Mar 31, 2026 · derived
Price
Oct 23, 2026 · Official close
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $39,552,000 | reported | |
| FY 2024 | 2024-12-31 | $57,800,000 | reported | |
| FY 2023 | 2023-12-31 | $176,232,000 | reported | |
| FY 2022 | 2022-12-31 | $111,299,000 | reported | |
| FY 2021 | 2021-12-31 | $110,701,000 | reported | |
| FY 2020 | 2020-12-31 | $118,192,000 | reported | |
| FY 2019 | 2019-12-31 | $102,428,000 | reported | |
| FY 2018 | 2018-12-31 | $84,452,000 | reported | |
| FY 2017 | 2017-12-31 | $36,567,000 | reported | |
| FY 2016 | 2016-12-31 | $19,389,000 | reported | |
| FY 2015 | 2015-12-31 | $39,539,000 | reported | |
| FY 2014 | 2014-12-31 | $45,870,000 | reported |
Biological products, except diagnostic substances
Sangamo Therapeutics, Inc is the 48th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
BSEMBioStem Technologies, Inc.$47.5M31.8%13.9%$24.7MFENCFennec Pharmaceuticals Inc.$44.6M6.1%21.8%$381.4MCHRSCoherus Oncology, Inc.$42.2M59.8%398.4%$83.4MEDITEditas Medicine, Inc.$40.5M25.4%395.0%$329.5MVYGRVoyager Therapeutics, Inc.$40.4M49.5%296.5%$105.8M
SGMOQSangamo Therapeutics, Inc (this company)$39.6M31.6%310.8%$49.7M
KYMRKymera Therapeutics, Inc.$39.2M16.7%794.0%$10.9BCCCCC4 Therapeutics, Inc.$35.9M1.0%292.1%$405.1MXFORX4 Pharmaceuticals, Inc$35.1M1,273.2%225.6%$324.2MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Sangamo Therapeutics, Inc · CIK 1001233 · Engraved from SEC EDGAR